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X-ray crystallographyG-protein coupled receptors (GPCRs) are integral membrane cell surface receptors with key roles in mediating
the cellular responses to a wide range of biologically relevant molecules including hormones, neurotransmitters
and importantly the majority of currently available drugs. The ﬁrst high-resolution, X-ray crystallographic
structure of a GPCR, that of rhodopsin, was obtained in 2000. It took a further seven years for the next structure,
that of the β2 adrenergic receptor. Remarkably, at the time of writing, there have been an astonishing 18 further
independent high-resolution GPCR structures published in the last ﬁve years (overall total of 68 structures in
different conformations or bound to different ligands). Of particular note is the recent structure of the β2 adren-
ergic receptor in complex with its cognate heterotrimeric G-protein revealing for the ﬁrst timemolecular details
of the interaction between a GPCR and the complete G-protein. Together these structures have provided unprec-
edented detail into themechanism of action of these incredibly important proteins. This reviewdescribes several
key methodological advances that have made such extraordinarily fast progress possible.
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G-protein coupled receptors are key modulators of cellular function.
These integralmembrane cell surface receptors form a speciﬁc, selectiveImperial College London, South
4; fax: +44 20 7594 3022.
ights reserved.binding site for a cognate ligand on the extracellular side of the mem-
brane. Interaction between the ligand (agonist) and the receptor results
in conformational changes in the receptor which allows recruitment
and activation of one or more of a small number of heterotrimeric
G-proteins. Activation of the G-protein results in exchange of the GDP
bound to the alpha subunit for GTP and dissociation of the alpha subunit
which then leaves both the alpha subunit and the beta-gamma dimer
free to interact with other downstream effector molecules [1]. Many
2584 N. Bertheleme et al. / Biochimica et Biophysica Acta 1828 (2013) 2583–2591GPCRs are able to activate G-protein in the absence of a stimulating
ligand, in other words they have constitutive activity [2,3]. There is
also a range of inhibitor molecules which can either block agonist-
induced activity (neutral antagonist) or block both agonist induced
and constitutive activity (inverse agonist). It is also becoming increas-
ingly clear that some receptors can interact with different downstream
effector systems depending on the chemical nature of the stimulatory
ligand bound [4]. All of these different receptor behaviors are likely to
be associated with different receptor conformations [5]. This highlights
one of the key issues associated with attempting to structurally charac-
terize GPCRs; that of their highly dynamic nature. In addition to the
standard issues associated with large scale expression and puriﬁcation
of eukaryotic membrane proteins, this dynamic nature made the
structural characterization of GPCRs particularly difﬁcult. This review
describes several different methodological approaches which have
contributed to reducing conformational ﬂexibility while concomitantly
increasing the stability of GPCRs sufﬁciently to allow efﬁcient crystalli-
zation and high resolution structure determination. A summary table
(Table 1) is provided with the key methodological advances which
have resulted in some example GPCR structures.
2. Expression of GPCRs
Rhodopsin was the ﬁrst GPCR to be structurally characterized [6].
Rhodopsin is unusual among GPCRs in that it expresses naturally at
very high levels and this was a major contributory factor to successful
structure determination. There are a number of structures of rhodopsin
in a range of different conformations and most of these have been
obtained using protein from natural sources [7–9]. However, thermo-
stable mutants of rhodopsin have also been expressed recombinantly
and protein produced in mammalian cells has led to high resolution
structures [10–13]. Of the recent 68 high resolution structures of
G-protein coupled receptors almost all have been obtained fromprotein
expressed in insect cell expression systems which combine the advan-
tages of higher eukaryotic protein processing mechanisms with
comparatively straightforward large scale expression. However the
structure of the human adenosine A2A receptor (A2AR) obtained in com-
plex with a Fab fragment [14] and the Histamine H1 receptor [15], were
obtained using protein produced in the methylotrophic yeast Pichia
pastoris. The ease of use of the P. pastoris expression vectors and the
ability to grow to very high cell densities have made Pichia an attractive
host for production of GPCRs [16,17]. To date no GPCR structures have
been reported using protein from the other popular yeast expressionTable 1
Selected examples of structurally characterized GPCRs.
Receptor Reference PDB accession
code
Notes on expression, isolation and crys
Bovine rhodopsin [6] 1F88 From native source, crystallized using n
Human β2AR [32] 2RFR Receptor expressed in insect cells, crys
only partial resolution of the protein.
Human β2AR [29] 2RH1 Receptor expressed in insect cells as a T
Turkey β1AR [54] 2VT4 Thermostabilized receptor obtained by
Human β2AR [66] 3P0G Receptor crystallized in an agonist bou
analog.
Human β2AR + Gs
protein complex
[49] 3SNG Receptor crystallized in the agonist bou
receptor, MNG-3 used, nanobody stabi
Human A2AR [14] 3VG9 Receptor expressed in Pichia pastoris, c
conformation. Crystallization by vapor
Human NTSR1 [58] 4GRV Thermostabilization + T4L fusion appr
Human A2AR [47] 4EIY A2AR + cytochrome b562RIL fusion pro
Human CXCR1 [87] 2LNL Receptor protein expressed in E. coli an
solid state NMR techniques
These receptors included in the table were chosen as they illustrate the different techniques an
have been solved see http://blanco.biomol.uci.edu/mpstruc/listAll/list. Thiswebsitemaintained
recent structure information.system, Saccharomyces cerevisiae, although there are a number of re-
ports of high level functional expression of receptors in these systems
[18]. Most recently there is a solid state NMR structure of the protein
backbone CXCR1 chemokine receptor which has been obtained using
protein produced in Escherichia coli as inclusion bodies and then
refolded [19]. A major limitation to NMR studies of membrane proteins
is the cost of the expression media used to produce isotopically labeled
proteins. The CXCR1 structure has shown the feasibility of producing
large quantities of functional labeled GPCR using the comparatively in-
expensive E. coli expression system. This will allow dynamic structural
studies on GPCRs in the membrane environment, building on the
ﬁndings of earlier studies [20,21]. E. coli has also been used to produce
protein which has yielded a structure of a thermostabilized, T4L free
form of the neurotensin-1 receptor (unreleased PDB ID: 3ZEV).
Although the manuscript describing this was unavailable at the time
ofwriting, these results indicate thatwith the correct construct it is pos-
sible to produce GPCRs in a bacterial system for structural studies.
3. Genetic modiﬁcation of GPCRs
Minormodiﬁcations of GPCRs have long been known to signiﬁcantly
change the recombinant expression level. The extended soluble
C-terminal tail of the GPCRs is located on the intracellular side of the
membrane and has key roles in receptor regulation [22]. Many
C-terminal tails are palmitoylated, containing additional lipid groups
which anchor this often large and relatively unstructured region of the
protein to the membrane. Over 20 years ago Parker and Ross [23]
demonstrated that the removal of the avian β-adrenergic receptor
C-terminal tail increased expression. Additional studies have revealed
that the C-terminal tail of the A2AR undergoes degradation following ex-
pression in both E. coli [24] and P. pastoris [16,25]. Even in cases where
the presence of the C-terminal tail has no major effect on expression,
the presence of such a ﬂexible domain is likely to be detrimental to
the formation of well-diffracting crystals. It is now standard practice
to remove the C-terminal tail prior to expression of any GPCR for struc-
tural studies. Research on the neurotensin-1 receptor (NTSR1) also
showed the requirement to remove the N-terminal 43 amino acids
due to proteolytic cleavage during expression in E. coli [26]. Removal
of N-terminal residues has also been used for other GPCRs including
the β1 adrenergic receptor [27].
Early studies on the expression of NTSR1 in E. coli demonstrated the
validity of the addition of tags to both theN andC-termini, principally to
increase expression levels but also facilitate isolation [26]. This approachtallization
onylglucoside and heptanetriol and the vapor diffusion technique.
tals obtained in complex with a Fab fragment using bicelle crystallization,
4L fusion, antagonist bound inactive form of the receptor crystallized in LCP.
alanine scanning mutagenesis. Construct crystallized in OTG using vapor diffusion.
nd active state in LCP. Conformation stabilized by a nanobody acting as a G-protein
nd active state in LCP. T4L used to replace the unstructured N-terminus of the
lized the heterotrimeric G-protein.
rystallized in complex with a Fab fragment stabilizing the antagonist binding
diffusion.
oach, MNG detergent and LCP.
tein crystallized in LCP. Improved crystal packing resulted in a resolution of 1.8 Å.
d refolded, Cα backbone modeled on rhodopsin obtained in phospholipid bilayer using
d approaches outlined in the main text. For a complete list of the receptor structures that
by Prof StephenWhite, UC Irvine is regularly updated and is the best resource for themost
Fig. 1. Three-dimensional structures of the β2ARwith the T4L fusion protein (A) replacing
ICL3 (PDB ID: 2RH1 [29]) and (B) at the N-terminus (PDB ID: 4GBR [48]).
2585N. Bertheleme et al. / Biochimica et Biophysica Acta 1828 (2013) 2583–2591was subsequently utilized and reﬁned for the production of a range of
GPCRs. For example, high-throughput expression studies of large
numbers of GPCRs in P. pastoris used a standardized tagging approach
involving the addition of N-terminal His and Flag tags and a
C-terminal Bio tag [16]. In these expression constructs, the genes of in-
terest were ﬂanked by sequences coding for proteolytic cleavage sites
allowing removal of the tags following protein isolation. However,
these genetic modiﬁcations were not sufﬁcient to allow crystallization
of the proteins even when large amounts of highly pure, functional
protein could be obtained.
4. Fusion protein approach
A substantial breakthrough in the structural studies of GPCRs came
with the adoption of fusion protein approaches. This is not just a simple
case of fusing an extra domain onto the N or C-terminus of a receptor
but of replacing the ﬂexible regions with an ordered protein. This
approach was initially applied to the bacterial transporter, LacY, as a
means of increasing the chances of obtaining crystals [28]. With respect
to GPCRs, theﬁrst use of fusion proteinswas for theβ2 adrenergic recep-
tor (β2AR) [29]. The third intracellular loop (ICL3) is a key region for
interaction with G-protein and in most receptors is highly ﬂexible. An
exception is the squid rhodopsin which is reported to have a compara-
tively rigid ICL3 [30]. A number of constructs were made replacing the
relatively ﬂexible and functionally important ICL3 of β2AR [31]. The
researchers chose T4 lysozyme (T4L) which not only has a high propen-
sity to crystallize but also has N and C-termini approximately the same
distance apart as that predicted for the cytoplasmic ends of the trans-
membrane domains (TMDs) V and VI of the receptor. In other words,
the T4L should ﬁt in the gap left by the deleted ICL3. The β2AR–T4L
fusion protein submitted to crystallization trials used the T4 lysozyme
to replace residues 231 to 262 of the receptor. The fusion protein was
shown to have similar ligand binding properties to the wild-type
but did not couple to the G-protein as the T4L sterically prevents the
G-protein from docking to the receptor. Crystals of the β2AR–T4L fusion
protein were obtained by the lipidic cubic phase (LCP) technique using
monoolein containing cholesterol and the structure was solved to 2.4 Å
[29] (Fig. 1A). Comparison with the structure of the β2AR obtained in
complex with a Fab (antigen binding fragment) revealed that the two
structureswere very similar ([32] see below formore details) indicating
that the presence of the T4L had not greatly altered the structure of
the receptor and showing the validity of this approach. This approach
has been successfully used by the groups of Stevens and Kobilka to ob-
tain crystals of a range of different GPCRs in complex with antagonists:
human A2AR [33]; human dopamine D3 receptor [34]; CXCR4 chemo-
kine receptor [35]; humanhistamineH1 receptor [15]; δ-opioid receptor
[36]; human κ-opioid receptor [37]; μ-opioid receptor [38]; the musca-
rinic M2 [39] and M3 [40] receptors; the sphingosine-1-phosphate
receptor [41]; the protease-activated receptor 1 [42] and the NTSR1
[43]. However this approach has also been successfully applied to
the structure determination of an agonist bound state of the A2AR
[44]. In each case the insertion was essential for obtaining well-
diffracting crystals, with the T4L mediating the crystal contacts. All of
these receptor T4L fusion proteins have been expressed in insect cells
with the exception of the histamine H1 receptor [15] which was pro-
duced in the methylotrophic yeast P. pastoris, demonstrating that this
approach can be successfully utilized in more than one expression
system.
The T4L fusion protein approach has been shown to havewide appli-
cability to GPCRs, however there are reports that it is not suitable for all
receptors [45]. Further work by the group of Ray Stevens identiﬁed a set
ofﬁve alternative fusion partners based on the key criteria of appropriate
distance between the N and C-termini (between 6 and 14 Å) to allow
accommodation between TMDs V and VI of the fusion partner and pro-
pensity to crystallize [45]. The ﬁve proteins, a C-terminal fragment of
T4 lysozyme, ﬂavodoxin, xylanase, rubredoxin and a thermostabilizedcytochrome b562 (named cytochrome b562RIL), were identiﬁed by exten-
sive screening of the Protein Data Bank. Fusion proteins of both the β2AR
andA2ARwith allﬁve of the fusion partnerswere generated and assessed
in terms of expression, yield of isolated protein, thermostability and
crystallizability. Fusion proteins of both receptors + cytochrome
b562RIL were selected for crystallization trials based on two criteria.
Firstly, theywere selected on the basis of increased thermostability com-
pared to the T4 lysozyme fusion constructs as assessed by a ﬂuorescence
basedunfolding assay [46]. Secondly, theywere also selected on the basis
of efﬁcient diffusion through the lipidic cubic phase, a good indicator of
propensity to crystallize in this phase (see section below on lipidic
cubic phase crystallization for more details). Well-diffracting crystals
were obtained of both constructs. Crystals of the β2AR + cytochrome
b562RIL diffracted to a resolution of 2.8 Å, which did not represent an
improvement in resolution compared to the β2AR–T4L structures. How-
ever, theA2AR + cytochromeb562RIL crystals diffracted to 1.7 Åwith the
structure solved to 1.8 Å [47]. The increased resolution of this structure
revealed the presence of a number of water and lipid molecules in the
structure and provided insights into the allosteric regulation of the
receptor by sodium ions.
While most of the fusion proteins have involved replacement of the
ﬂexible ICL3, it is possible to attach the T4L to the N-terminus of the re-
ceptor [48] (Fig. 1B). This approach was used for the β2 adrenergic
receptor + G protein complex [49] (see also section on antibodies).
Subsequently the structure of the nociceptin/orphanin FQ receptor
[50] has also been solved as an N-terminal fusion protein with cyto-
chrome b562RIL. Thus there is ﬂexibility with the fusions with respect
to the attachment point aswell as the fusion partner which can be used.
5. Mutagenesis approaches to stabilizing GPCRs
Research on the diacylglycerol kinase (DAGK), a four transmem-
brane domain protein from E. coli showed that systematic mutagenesis
used in combination with functional analysis could be used to identify
mutants which retained function but had dramatically increased
thermostability [51] compared towild-type. Themost stable DAGK con-
struct contained four point mutations and had a half-life of 35 min at
80 °C in the comparatively harsh, C8 detergent, octylglucoside (OG)
compared to the wild type with a half-life of less than a minute at
55 °C in dodecyl-β-D-maltoside (DDM). The high resolution structures
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ly been solved [52]. This approach has also been extremely successfully
applied to the thermostabilization of GPCRs. In the case of the GPCRs it
has also proved possible to select for conformationally stablemutant re-
ceptors resulting in a number of high resolution structures in complex
with a range of different ligands.
The ﬁrst example was the β1 adrenergic receptor (β1AR) from tur-
key. Previous research had already generated an optimized construct,
truncated at both the N and C-termini which expressed well in insect
cells and was resistant to proteolytic degradation [27]. Of the 390
residues in the truncated construct 314 were individually mutated to
alanine and the function of themutants assessed by radioligand binding
analysis following heat treatment at 32 °C (the apparent Tm of thewild-
type protein) for 30 min. This analysis identiﬁed a number of mutants
which had increased stability and thus functionality compared to the
wild-type. Iterative rounds ofmutagenesis combining different thermo-
stabilizingmutants resulted in a receptor construct, m23, containing six
point mutations and a Tm 21 °C higher than the wild-type [53]. This re-
ceptor was shown to preferentially bind antagonist indicating reduced
conformational ﬂexibility. In addition, them23wasmarkedlymore sta-
ble in short-chain detergents than the wild-type. These features
resulted in a receptor which was much more suitable for structural
studies than the wild-type and the structure was ultimately solved
using crystals of them23 obtained in octylthioglucopyranoside, a C8 de-
tergent [54].
The same approach has been applied to the A2AR [55] and NTSR1
[56,57]. For the NTS1 the thermostabilization approach alone has not
been shown to produce protein suitable for structural studies [58],
(see below in section on Combinations of approaches). However it has
resulted in a number of A2AR structures in complex with a range of li-
gands [59,60]. Analysis of some of the thermostable A2AR mutants in a
yeast based cell signaling assay revealed that these receptors had lost
constitutive activity [61] and this may explain at least in part why
they are much more stable than the wild-type. A Biotech company,
Heptares, is applying this approach to a range of different GPCRs with
reportedly great success.
6. Complex formation with antibody fragments
The use of antibody fragments to facilitate crystallization has been
successfully applied to a range of membrane protein structures. The
aim of this type of approach is to increase the size of the soluble domain
of the target protein through high afﬁnity association with a structure
speciﬁc antibody fragment. This is also likely to result in stabilization
of a speciﬁc conformation of the target membrane protein. The ﬁrst ex-
ample of structure determination of a membrane protein in complex
with an antibody fragment was the cytochrome c oxidase from
Paracoccus denitriﬁcans [62]. Subsequently this approach has also been
successfully applied to the bc1 complex from yeast [63] as well as the
ClC chloride channel [64] and the voltage gated K+ channel [65].
The use of antibody fragments seemed a logical approach for
GPCRs. Indeed the ﬁrst structure of a non-rhodopsin GPCR, the
β2AR [32] was obtained in the presence of a Fab fragment which
bound to the third intracellular loop. The structure was solved to
3.4 Å and provided information on the overall architecture of the he-
lices and loops. While at the time this represented a step forward in
GPCR structural studies, the impact of the structure was limited by
the fact that only approximately two-thirds of the receptor was or-
dered. Approximately one third of the transmembrane domains
and the extracellular loops could not be resolved. Very soon after
this came the structure of the human β2AR expressed as a fusion pro-
tein with the ICL3 replaced with T4L [29]. The antibody fragment
β2AR complex structure was particularly useful here as the high de-
gree of similarity between the T4L and the antibody receptor struc-
tures revealed that the presence of T4L did not signiﬁcantly alter
the orientation of the transmembrane helices. Taken togetherwith functional data demonstrating maintained high afﬁnity ligand
binding this ﬁnding gave conﬁdence that the structure of the
β2AR + T4L was physiologically relevant.
The β2AR + T4L has subsequently been crystallized in an active
form in complex with a nanobody [66]. Nanobodies are single domain
proteins engineered from heavy chain only camelid antibodies. They
are both smaller than and have been shown to have greater stability
than conventional antibodies as well as Fab and scFv fragments. The re-
searchers relied on a very high afﬁnity β2AR agonist (BI71067) with a
slow off rate to stabilize the receptor in the active form prior to injection
of the protein into a llama in order to raise the antibodies [67]. The ﬁnal
generated nanobody, Nb80, bound to the intracellular side of the β2AR
and increased the binding afﬁnity of the receptor for agonist [66]. It is
thus thought that the nanobody acts as a G-protein analog. The third
complementarity determining region of the nanobody extended into
the core of the receptor stabilizing the outward movement of the cyto-
plasmic end of TM6 [66] a conformational change central to adopting
the active receptor conformation.
A nanobody also contributed to the structure determination of the
β2AR + Gαs protein complex [49]. Obtaining well-diffracting crystals
of this complex represented a signiﬁcant technical challenge. The use
of the high afﬁnity β2AR agonist, BI71067, allowed the formation of
the β2AR + Gαs protein complex in DDM solution. The use of MNG-3
(Fig. 5B, see more details below in section on detergents) as an alterna-
tive to DDM increased the stability of the complex. The unstructured N-
terminus of the receptor was replaced with T4 lysozyme. Several con-
structs were generated and analyzed by single particle analysis in
order to obtain the optimum orientation of the T4 lysozyme relative to
the receptor. The proteinwas also crystallized in the presence of the py-
rophosphatemimic, foscarnate,which stabilizes theGαs subunit. Finally,
in order to stabilize the interface between the subunits of the G-protein,
a nanobody, Nb35, which bound to both the Gαs and Gβ subunits was
also used. Identiﬁcation of both the best nanobody and conditions for
optimal stability (minimal heterogeneity) of the complex was facilitat-
ed by the use of single particle EM [68]. Both the nanobody and the
T4Lwere involved in the formation of crystal contacts essential for crys-
tal lattice formation. This was the ﬁrst and so far the only structure re-
vealing details of the precise molecular interactions between a
receptor and a heterotrimeric G-protein (Fig. 4).
Success has been achieved with the application of more conven-
tional antibodies to the structure determination of the inactive
human A2AR [14]. As in the human β2AR the Fab fragment bound
to the intracellular loops of the A2AR locking the receptor into an
antagonist binding form. This essentially has the same effect as
thermostabilizing the protein through reducing the conformational
ﬂexibility. The receptor–Fab complex was solved to a reported reso-
lution of 2.7 Å (Fig. 2) and the structure is almost identical to those
obtained using the T4L-fusion protein [33] and thermostabilization
through mutagenesis [59] approaches. The Fab fragment forms an inti-
mate contact with the receptor by penetrating a pocket formed by TM2,
3, 6 and 7. Although the receptor conformations are distinct, the Fab
binds to a similar region of the receptor to that of the nanobody in the
structure of the active conformation of the β2AR [66]. Interestingly the
human A2AR–Fab complex structure is one of only two GPCR structures
obtained using receptor protein expressed heterologously in the
methylotrophic yeast, P. pastoris.
7. G-protein peptides
As described above it has been possible to obtain a high-resolution
structure of the β2AR in complex with its cognate heterotrimeric
G-protein [49]. However, previous research has shown it is not neces-
sary to use thewhole G-protein to obtain information on the interaction
surface. The unliganded form of rhodopsin, opsin in the active Ops*
form, was crystallized in complex with a synthetic mutant high afﬁnity
peptide corresponding to the C-terminus of the Gα [69]. The 11-amino
Fig. 2. Superposition of the three-dimensional structures of the inactive A2AR obtained using three differentmethods: T4L fusion protein (magenta, PDB ID: 3EML [33]), thermostabilization
(green, PDB ID: 3PWH [59]) and antibody (cyan, PDB ID: 3VG9 [14]). Extracellular (A) and intracellular (B) views of the protein are shown.
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approach allowed insights into the interaction between the receptor
and G-protein without the need for reconstitution of a receptor–full
G-protein complex. The same strategy was employed in obtaining the
structure of a constitutively active form of rhodopsin [11]. Given the
comparative ease of generating such G-protein peptides, this approach
may be suitable for other GPCRs. It is worth noting that the structure
of Ops* in complex with the synthetic peptide is very similar to that of
the ligand free Ops* in the absence of peptide [70]. However a compar-
ison of the different structures reveals that TM6 in the Ops* structure
does not move as far away from the core of the protein as in the
β2AR–Gαs complex structure (Fig. 3). It is not clear why there is this dif-
ference in the orientation of TM6 in the two structures; however, fur-
ther investigation is necessary to demonstrate that the G-protein
peptides can act as an exact replacement for the complete G-protein.
At the time of writing a new structure was solved which used the
peptide method in a different way. Shukla et al. obtained a structure
of an active form of β-arrestin-1 in complexwith a phosphorylated pep-
tide of the C-terminus of the vasopressin receptor [71] and an antibodyFig. 3. Superposition of the three-dimensional structures of the active form of the opsin in
complex with a small peptide (green, PDB ID: 3DQB [69]), the active form of the β2AR in
complex with Gαs protein (yellow PDB ID: 3SN6 [49]) and with a nanobody (magenta
PDB ID: 3P0G [66]) and the inactive form of the β2AR (gray PDB ID: 2RH1 [29]). The intra-
cellular view of the protein is shown illustrating in particular the relative movements ob-
served for TM6 and TM5 upon receptor activation.which stabilized the activated form of the arrestin. This illustrates that
peptides of both receptor and G-protein can be used effectively.
8. Use of a novel class of detergents
Theﬁrst GPCR to be structurally determined, rhodopsin [6]was crys-
tallized in nonylglucoside together with the additive 1,2,3-heptanetriol
using the vapor diffusion technique. The majority of the GPCR crystal
structures obtained since then, including the T4L fusion proteins are
the result of lipidic cubic phase crystallization (see below and [72]). In
these cases the GPCRs have been isolated in DDM and then exchanged
out of the detergent and into the lipid phase during the crystallization
process. In the case of the thermostabilized receptors, these are typically
much more stable in short chain detergents than the wild-type forms
[53,55,57]. The thermostabilized β1AR and A2AR were successfully
crystallized using vapor diffusion in the short-chain detergents
octylthioglucopyranoside (OTG) and nonylglucoside (NG) respectively.
In addition to all these successes using standard, commonly used
detergents, signiﬁcant progress has been made in the development of
novel amphiphiles which confer greater stability on integral membrane
proteins than standard detergents. Of particular note are the maltose-
neopentyl glycol (MNG) amphiphiles [73]. These agents contain a cen-
tral quaternary carbon atom, a branched tail region and a branched
head group (Fig. 5B). It is thought that the unique architecture of this
class of detergents results in greater stability of the MNG micelles,
illustrated by the fact that even at concentrations well below the CMC,
the MNGs are able to maintain membrane proteins in solution. The
MNGs also confer greater stability on a range of different membrane
protein molecules. Stability analysis revealed that the presence of the
MNGs increased the Tm of the β2AR + T4L compared to DDM [73]. Of
all the detergent molecules tested MNG-3 (Fig. 5B) proved to be the
best agent for bothβ2AR + T4L and a range of other integralmembrane
proteins. Subsequent to these studies a number of GPCRs have been
isolated in MNG-3 prior to crystallization using lipidic cubic phase in-
cluding the M2 muscarinic acetylcholine receptor [39] and the δ- [36]
and μ-opioid [38] receptors. In addition the β2AR–Gαs complex was sta-
bilized in MNG-3 prior to crystallization in lipidic cubic phase [49]
(Fig. 4). It takes longer for crystals to form in lipidic cubic phase than
in vapor diffusion. The greater stability conferred by MNG-3 means
that the isolated receptors are more likely to remain intact for the ex-
tended time required to form the crystals.
To date no GPCR structures have been obtained using the MNG-3
and vapor diffusion crystallization. However, very recently the structure
of TatC, an integral membrane component of the twin arginine protein
Fig. 4. Three-dimensional structure of the β2AR (green) in complex with the Gs protein
(PDB ID: 3SN6 [49]). The T4L fusion protein is shown in magenta, the Gα in gray, the Gβ
in cyan, the Gγ in yellow and the nanobody in red.
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diffusion [74] showing the suitability of this detergent for vapor diffu-
sion crystallization. In addition the structure of an integral membrane
pyrophosphatase [75] has been obtained in a related but smaller deter-
gent molecule; glucose neopentylglycol (GNG) [76]. This detergent has
a smaller headgroup and a shorter alkyl chain (Fig. 5A). It is possible that
this amphiphile may bemore suitable for vapor diffusion crystallization
of GPCRs than theMNGs because of its tendency to form small protein–Fig. 5.Chemical structures of (A)GNG-3 and (B)MNG-3. Bothmolecules contain a central quate
diglucoside head group and two C8 alkyl chains while MNG-3 contains a dimaltoside head grodetergent complexes. Further advances in the area of alternative deter-
gents have the potential to facilitate structural studies of GPCRs as well
as other integral membrane proteins [77,78].
9. LCP crystallization
While several GPCR structures have been obtained from vapor diffu-
sion crystallization, the largest number of structures has been obtained
from lipidic cubic phase (LCP) methods. LCP crystallization involves the
use of a bicontinuous lipid matrix, usually made up of the lipid
monoolein, containing solvent channels [72]. Over time the detergent
solubilized membrane protein exchanges into the lipid and given
optimal conditions will form 3-dimensional crystals with a packing
that resembles stacks of 2-dimensional crystals. The ﬁrst example of a
membrane protein crystallized using the LCP technique was bacterio-
rhodopsin [79]. The crystals were obtained using the lipid monoolein
and the structure was initially solved to 3.7 Å with a subsequent struc-
ture solved to 1.4 Å [80]. This technique was successfully used to crys-
tallize a number of different membrane proteins but the most striking
early successes were made with other 7TM proteins; halorhodopsin
[81] and sensory rhodopsin II [82,83]. This was strongly indicative that
LCP crystallizationwas suitable for theGPCRs. Initial attempts to crystal-
lize a range of GPCRs in LCP failed, probably as a result of low stability of
the isolated proteins. The T4L fusion proteins have subsequently been
shown to be amenable to crystallization in LCP with almost all the key
crystal contacts formed by the T4L (Table 1). While monoolein is the
lipid preferentially used for GPCR crystallization, cholesterol is also usu-
ally added [29,33,40,50] which increases the stability of the GPCR in the
lipid phase.
The development of a generic protein thermal denaturation
assays has allowed the comparative analysis of a range of different
constructs or buffer conditions onmembraneprotein stabilization in so-
lution [46]. This assay uses the N-[4-(7-diethylamino-4-methyl-3-
coumarinyl)-phenyl]maleimide) (CPM) dye which has low intrinsic
ﬂuorescence but becomes highly ﬂuorescent upon binding to free cyste-
ine residues exposed upon protein unfolding. Although it is more com-
plicated to do the same type of analysis in lipid phases a range of
different techniques have been developed to explore the stability of
membrane proteins in LCP. Changes in protein stability can be assessed
based on changes in the intrinsic ﬂuorescence of proteins following
heating [84]. Studies on bacteriorhodopsin revealed amarked difference
in stability of the protein in phases made from different lipids. The LCP-
Tm assay describes the use of the CPM dye [85] for direct analysis of the
folded state of GPCR which has been incorporated into LCP. There is a
somewhat time-consuming heating and centrifugation process required
to ensure changes in the LCP do not interferewith theﬂuorescencemea-
surements. However, this method has signiﬁcant potential to facilitate
investigations on the effects of different conditions including different
receptor ligands and lipids on receptor stability in the LCP.
As a means of improving efﬁciency of GPCR crystallization in LCP,
Cherezov and his group have developed the LCP-ﬂuorescence recovery
after photobleaching (LCP-FRAP) method [86]. There seems to be arnary carbon atomwith branched head groups and branched tail regions. GNG-3 contains a
up and two C12 alkyl chain.
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the lipid phase and their propensity to crystallize. The GPCR molecules
were labeledwith Cy3-monoNHS ester and then reconstituted into a li-
pidic cubic phase of monoolein. A small area of the lipidic cubic phase
was bleached with a laser and the ﬂuorescence in that area assayed
for recovery (a measure of the diffusion of the labeled molecules) at
speciﬁed time points. Using this approach it was possible to assess the
diffusion of labeled A2AR and β2AR molecules in a high-throughput
format testing a wide variety of potential crystallization conditions.
The researchers showed that they could investigate receptor diffusion
using low protein concentrations (1 mg/ml) and achieve results repre-
sentative of the much higher concentrations used in crystallization tri-
als. This allows assessment of the suitability of a much greater number
of crystallization conditions using far less protein sample than the tradi-
tional crystallization trials [86].
10. Combinations of approaches
Many of the GPCR structures that have been obtained are the result
of more than one of themethods detailed above. For example the β2AR-
Gαs involved the generation of anN-terminal T4L fusion and the use of a
nanobody as well as the use of the MNG-3 amphiphile and LCP crystal-
lization [49]. Thus one approach is not guaranteed to provide well-
diffracting crystals, rather it is the combination of amultitude of factors.
In order to explore this further wewould like to brieﬂy cover the recent
structure of the NTSR1. The NTSR1 was the subject of a substantial
amount of pioneering research in the development of expression con-
structs and puriﬁcation protocols [26] almost 20 years ago. This early
study reported high levels of functional expression (800 receptors/
cell) in E. coli as a fusion with a C-terminal thioredoxin tag and highly
pure protein constructs. Despite the high quality of the isolated protein,
crystals proved elusive probably as a result of the intrinsic conforma-
tional ﬂexibility of the receptor. Attempts to thermostabilize the protein
in the unliganded state using the alanine scanning mutagenesis ap-
proach pioneered by the Tate group were successful, resulting in a
more stable NTSR1 construct containing 4 pointmutations [57]. The op-
timized construct had increased stability both in the absence (+17 °C)
and presence of ligand (+13 °C) compared to wild-type receptor. As
reported for the β1 and A2AR thermostabilized constructs the stabilized
NTSR1 was more stable than wild-type in short-chain detergents.
However this still was not enough to yield well-diffracting crystals
of the NTSR1. A completely fresh attempt at thermostabilization by
mutagenesis in the presence of agonist resulted in an apparent Tm
of 48 °C (+11 °C compared to wild-type) [56]. This mutant was used
to generate a T4L fusion protein with the T4L replacing ICL3 [58]. The
protein was expressed in insect cells and crystallized using MNG-3
and the lipidic cubic phase technique (see above). It should be men-
tioned that although the mutagenesis of the NTSR1 resulted in
maintained agonist binding, it inhibited the ability of the receptor to ac-
tivate G-protein [58].
As mentioned above it is important to gain an appreciation of
precisely what effects the mutagenesis has on the overall function of
the receptor protein. The example of the NTSR1 structure amply dem-
onstrates that combinations of approaches can be used to great effect.
The increase in the number of tools available means that researchers
have a range of individual approaches to choose from as well as combi-
nations as outlined here.
11. The future
The main focus of this review has been on the techniques which
have facilitated the X-ray crystallographic analysis of GPCRs. Over the
last ﬁve years or so these have led to a mini explosion in the number
of GPCR structures and a dramatic increase in our understanding of
the mechanism of action of these important proteins. However the ma-
jority of structures that have been obtained are of receptors that haveundergone quite radical changes. In addition, the X-ray crystal
structures are snapshots providing detailed images of static forms of
the receptors. Despite the groundbreaking achievements that have
beenmade, the ﬁeld is very much in its infancy as biological data reveal
evermore complexity in the behavior of GPCRs in biological contexts. In
order to truly understand the structure–function information for GPCRs
we need structural information revealing the dynamic changes involved
in dimer formation, ligand binding, G-protein and arrestin coupling and
the differences associated with constitutive activity compared to ago-
nist binding activity. Information is also needed on the precise nature
of ligand selectivity and the role of the C-terminus in receptor signaling.
It is also essential to understand the differences in receptor conforma-
tion induced by biased agonists and how these translate to association
with different effectors. In addition it is important to gain insight into
the precise role the membrane lipids have on receptor function. X-ray
crystallography will undoubtedly continue to make a signiﬁcant contri-
bution to the body of knowledge on GPCRs and help to answer some of
these questions however other techniques are starting to showpromise.
The structure of CXCR1 has also been solved in a more native environ-
ment using rotationally aligned solid state NMR in combination with
molecular fragment replacement [87]. Interestingly, the labeled protein
used to generate this structure was expressed in E. coli as inclusion
bodies and refolded [19]. While this structure provides information
only about the protein backbone, solid state NMR has major potential
as a means of understanding dynamic changes in the receptor upon
ligand and G-protein interaction. In addition, there is for the ﬁrst time
the possibility to study the effect of protein–lipid interactions on recep-
tor behavior in a dynamic situation. This solid state NMR technique,
allows investigation of receptor structure and dynamics in an environ-
ment as close as possible to the physiological.
While solid-state NMR would appear to be the method of choice for
high resolution spectroscopic analysis of GPCRs since it allows study of
the proteins in a lipid environment, advances have also been made
with respect to solution state NMR and 7TM proteins. The solution
structure of sensory rhodopsin II in phospholipid bicelles [88] was
very similar to the X-ray crystallographic structure. One key feature of
this work was that the data was collected at 50 °C. Data collection at
this temperature was possible because of the intrinsic stability of senso-
ry rhodopsin.While nowild-type GPCR could withstand data collection
at this temperature, it may be possible to use this approach with the
thermostabilized receptor constructs generated by mutagenesis. The
dynamic information gained may provide insight into receptor–ligand
interactions. However the fact that these studies would be carried out
on genetically modiﬁed receptors which have already been structurally
characterized by X-ray crystallography would mean that it would pro-
vide only limited information. In contrast, the solid state NMR study de-
scribed above suffers no such limitations.12. Conclusions
In conclusion, a raft of technological developments has allowed
enormous strides to be made in our understanding of GPCR struc-
ture and function. Central to almost all of the high resolution struc-
tures that have been obtained, has been the stabilization of the
receptors by reducing conformational ﬂexibility. The static snap-
shots which have been obtained by X-ray crystallography have pro-
vided detailed insights into ligand binding and G-protein coupling
and highlighted remarkable similarities in the architecture and key
conformational changes in different receptors as well as revealing
some interesting receptor speciﬁc differences. There are estimated to
be roughly 800 G-protein coupled receptors in the human genome and
we can expect that X-ray crystallographic structures of many more of
these will be solved in the near future using the techniques outlined
here. While signiﬁcant advances have been made with respect to
GPCRs, as outlined above many questions remain. It is possible that
2590 N. Bertheleme et al. / Biochimica et Biophysica Acta 1828 (2013) 2583–2591solid state NMR techniques have signiﬁcant potential as a means of
studying GPCR dynamics of unmodiﬁed receptors.
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